Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
DICE Therapeutics, Inc. (DICE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Agreement and Plan of Merger by and among DICE Therapeutics, Inc., Eli Lilly and Company and Durning Acquisition Corporation, (incorporated by reference to Exhibit 2.1 to DICE Therapeutics Inc.’s Current Report on Form 8-K filed with the SEC on June 20, 2023).",
"Amended and Restated Certificate of Incorporation of DICE Therapeutics, Inc. *",
"Amended and Restated Bylaws of DICE Therapeutics, Inc. *"
06/07/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "DICE THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION DICE Therapeutics, Inc., a Delaware corporation, hereby certifies as follows: 1. The name of this corporation is “DICE Therapeutics, Inc.” The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was September 14, 2021 under the name DICE Therapeutics, Inc. 2. The Amended and Restated Certificate of Incorporation of this corporation attached hereto as Exhibit A, which is incorporated herein by this reference, and which restates, integrates and further amends the provisions of the Certificate of Incorporation of this corporation as previously amended and/or restated, has been duly adopted by this corporation’s Board of Directors and by the s..."
05/11/2023 8-K Quarterly results
Docs: "DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights • First patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasis • Topline data from Phase 1 clinical trial of second oral IL-17 inhibitor, DC-853, in healthy volunteers expected in 2H 2023 • Strong financial position with $554.5 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestones SOUTH SAN FRANCISCO, CA, May 11, 2023 – DICE Therapeutics, Inc. , a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today reported fi..."
03/15/2023 8-K Quarterly results
Docs: "DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights • IND application for DICE’s lead oral IL-17 antagonist, DC-806, cleared by FDA; global Phase 2b clinical trial in patients with moderate-to-severe psoriasis on track to initiate in 1H 2023 • First participants dosed in Phase 1 clinical trial of second oral IL-17 antagonist DC-853; topline data in healthy volunteers expected in 2H 2023 • Ended 2022 with $574.2 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestones SOUTH SAN FRANCISCO, CA, March 15, 2023 – DICE Therapeutics, Inc. , a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of nov..."
02/10/2023 8-K Quarterly results
11/17/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "RESTATED BYLAWS As Amended and Restated on November 14, 2022 DICE THERAPEUTICS, INC. RESTATED BYLAWS"
11/09/2022 8-K Quarterly results
Docs: "DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights • Reported positive Phase 1 proof-of-concept data supporting the further development of lead oral IL-17 antagonist, DC-806, as potential best-in-class oral agent for psoriasis • Demonstrated direct inhibition of a cytokine with a small molecule in psoriasis patients, which we believe validates the DELSCAPE platform and DICE’s approach to identifying and advancing oral medicines against protein-protein interactions in immunology • Completed $345 million upsized public offering providing funding into 2026 SOUTH SAN FRANCISCO, CA, November 9, 2022 – DICE Therapeutics, Inc. , a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therap..."
10/13/2022 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements...
Docs: "Underwriting Agreement",
"Opinion of Fenwick & West LLP",
"About DICE Therapeutics, Inc."
10/11/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis",
"Phase 1 Data Presentation"
08/11/2022 8-K Quarterly results
06/28/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
03/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/21/2022 8-K Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhib...
Docs: "DICE Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights"
02/17/2022 8-K Investor presentation
Docs: "Corporate Presentation",
"Corporate Presentation"
11/12/2021 8-K Quarterly results
Docs: "DICE Therapeutics Reports Third Quarter 2021 Financial Results and Recent Highlights"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy